ArticleISRN endocrinology2013
Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk.
Article in ISRN endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Dietary phenolic compounds as promising therapeutic agents for diabetes and its complications: A comprehensive review.Food science & nutrition · 2024Review
- Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2.Oncology letters · 2021Article
- Obesity and related conditions and risk of inflammatory breast cancer: a nested case-control study.Breast cancer research and treatment · 2020Article
- Article
- Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis.OncoTargets and therapy · 2018Article
- Exploring the Therapeutic Ability of Fenugreek against Type 2 Diabetes and Breast Cancer Employing Molecular Docking and Molecular Dynamics Simulations.Evidence-based complementary and alternative medicine : eCAM · 2018Article
- Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women.Epidemiology (Cambridge, Mass.) · 2017Article
- Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.Breast cancer research : BCR · 2015Article
- Convergence and divergence of genetic and modular networks between diabetes and breast cancer.Journal of cellular and molecular medicine · 2015Article
- The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey.Journal of gastroenterology · 2015Article
- Role of breast cancer inhibitors on diabetes mellitus- an in silico approach.Journal of diabetes and metabolic disorders · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is among the most common cancers worldwide. Diabetes is an important chronic health problem associated with insulin resistance, increased insulin level, changes in growth hormones and factors, and activation of mitogen-activating protein kinase (MAPK) pathways, leading to an increased breast cancer risk. This paper looked at the epidemiologic studies of the association between type 2 diabetes and risk of breast cancer and its effect on overall cancer-specific survival. The combined evidence overall supported a modest association between type 2 diabetes and the risk of breast cancer, which was found to be more prevalent among postmenopausal women. Effect of oral diabetics and insulin therapy on breast cancer risk was also evaluated. It was found that metformin and thiazolidinones tended to have a protective role. Metformin therapy trials for its use as an adjuvant for breast cancer treatment are still ongoing. Sulfonylurea and insulin therapy were found to be mildly associated with increased overall cancers. No evidence or studies evaluated the association of DPPIV inhibitors and GLP 1 agonists with breast cancer risk because of their recent introduction into the management of diabetes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.